
• Reported GAAP EPS of $2.69 up 14.47% YoY • Reported revenue of $1.42B up 10.98% YoY
Bullish
Resmed Inc. achieved 11% revenue growth driven by strong demand and expanded non-GAAP gross margins due to efficiencies, alongside securing FDA clearance for an AI-enabled digital medical device.
Bearish
Resmed Inc. faced increased SG&A expenses relative to revenue and recorded $6 million in restructuring charges, while short-term debt also significantly increased during the quarter.